连续流左心室辅助装置植入的区域结局与不良事件比较:IMACS分析
基于IMACS注册数据库15560例成人连续流LVAD植入患者,比较美洲、亚太和欧洲在患者选择、生存率和不良事件上的区域差异。结果显示区域间在年龄>70岁、病态肥胖、男性比例、destination therapy及离心泵使用率上存在显著差异,生存率随区域和泵流类型而异,提示全球LVAD实践异质性可能影响长期生存。
要点
- 区域间LVAD患者选择差异显著,如>70岁植入率美洲14%、亚太1%、欧洲5%。
- destination therapy比例区域差异大:美洲48%、亚太4%、欧洲22%。
- 生存率随区域和泵类型变化,欧洲离心泵48个月生存率53%低于亚太74%。
核心结论
- 全球LVAD受者特征、装置使用和术后管理存在显著区域差异,可能影响长期生存。
研究设计与样本
- 基于IMACS注册数据库的回顾性分析,纳入15560例成人连续流LVAD植入患者,其中9988例(64%)为轴流泵,5572例(36%)为离心泵。
主要发现
- 年龄>70岁植入率:美洲14%、亚太1%、欧洲5%(p<0.0001)。
- 病态肥胖比例:美洲5%、亚太1%、欧洲1%(p<0.0001)。
- 男性比例:美洲79%、亚太77%、欧洲85%(p<0.0001)。
- destination therapy比例:美洲48%、亚太4%、欧洲22%(p<0.0001)。
- 离心泵使用率:美洲30%、亚太34%、欧洲74%(p<0.0001)。
关键数值与推荐
- 12个月生存率(轴流vs离心):美洲82% vs 82%,亚太92% vs 86%,欧洲80% vs 75%。
- 48个月生存率(轴流vs离心):美洲52% vs 53%,亚太83% vs 74%,欧洲69% vs 53%。
- 区域生存率差异p<0.0001。
临床怎么用
- 临床应关注区域间LVAD患者选择和装置使用的差异,个体化评估远期生存。
局限性
- 原文未报告局限性相关内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Regional outcomes after implantation of continuous-flow left ventricular assist devices (LVADs) have not been described. We examined differences in patient selection, survival, and adverse events across 3 geographic regions of the world: the Americas, Asia-Pacific, and Europe. METHODS: Using data from The International Society for Heart and Lung Transplantation Mechanically Assisted Circulatory Support registry, all adult patients implanted with a continuous-flow LVADs were included in this International Society for Heart and Lung Transplantation Mechanically Assisted Circulatory Support analysis (n = 15,560), of whom, 9,988 (64%) received axial-flow devices and 5,572 (36%) received centrifugal-flow devices. RESULTS: There were significant interregional differences in the rate of implantation of patients aged >70 years (Americas: 14%, Asia-Pacific: 1%, Europe: 5%; p < 0.0001), morbidly obese (Americas: 5%, Asia-Pacific: 1%, Europe: 1%; p < 0.0001), male (Americas: 79%, Asia-Pacific: 77%, Europe: 85%; p < 0.0001), and implanted as destination therapy (Americas: 48%, Asia-Pacific: 4%, Europe: 22%; p < 0.0001). The rates of centrifugal pump usage varied by region (Americas: 30%, Asia-Pacific: 34%, Eu: 74%; p < 0.0001). Survival rates varied by region and the type of pump flow, with survival at 12 and 48 months (axial flow vs centrifugal flow) being 82% vs 82% and 52% vs 53 in Americas; 92% vs 86% and 83% vs 74% in Asia-Pacific; and 80% vs 75% and 69% vs 53% in Europe, respectively (regional survival p < 0.0001). CONCLUSION: There are marked global differences in LVAD recipient characteristics, device utilization, and post-operative care. These heterogeneities along with differences in patient management and transplantation rates may impact long-term survival. Regional differences in adverse event incidence warrant further investigation.
引用
- Mirza KK, Xie R, Cowger J, et al. Comparative analysis of regional outcomes and adverse events after continuous-flow left ventricular assist device implantation: An IMACS analysis. J Heart Lung Transplant. 2020. PMID: 32487472. doi:10.1016/j.healun.2020.05.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。